Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Update: Amid Fears Of Trump Pressure, Fauci Warns Of Rushing Vaccine Authorization

Plus: Imperial Joins Phase I Frontrunners, Cellivery's Anti-inflammatory

Executive Summary

Anthony Fauci says a hasty emergency use authorization for a vaccine would be a mistake - and the FDA commissioner will not be drawn on timelines.

You may also be interested in...



Sanofi Bets Big On mRNA Vaccines With Expanded Translate Pact

Sanofi and Translate Bio, which hope to advance their mRNA vaccine candidate into a first-in-human clinical trial in the fourth quarter of 2020, have significantly extended their collaboration in that field, with the French giant plonking down a whopping $425m upfront fee.

Hetero, Cipla's Remdesivirs Hit India Market, 'Surplus' Envisaged By August

Gilead licensees Hetero and Cipla introduce remdesivir, the antiviral seen as a potential treatment for COVID-19, in India. Pricing plans will be closely watched and supplies in the country are expected to stabilize soon, possibly turning to a surplus situation in several months.

Roche Bolsters India Partnering With Cipla, Entero To Handle Nephrology

Roche is pressing ahead with partnering deals in India as part of efforts to expand access to certain key existing brands and signals intent to continue to explore more collaborations wherever it needs to “reach out to more patients urgently.”

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel